varenicline has been researched along with Idiopathic Parkinson Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abreu-Villaça, Y; Araújo, UC; Filgueiras, CC; Isnardo-Fernandes, J; Leal-Rocha, PH; Manhães, AC; Ribeiro-Carvalho, A | 1 |
| Albin, RL; Bohnen, NI; Dauer, WT; Kim, K; Koeppe, RA; Lustig, C; Müller, MLTM; Sarter, M; Spino, C; Szpara, A | 1 |
| Açikalin, Ö; Bölükbaşi Hatip, F; Hatip-Al-Khatib, I; Kataoka, Y; Tan, R; Yamauchi, A | 1 |
| Kaakkola, S; Tuominen, R | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
1 review(s) available for varenicline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].
Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2013 |
4 other study(ies) available for varenicline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Varenicline | 2021 |
α4β2
Topics: Aged; Brain; Cross-Over Studies; Female; Gait; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Nicotinic Agonists; Parkinson Disease; Positron-Emission Tomography; Postural Balance; Varenicline | 2021 |
Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Motor Activity; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substantia Nigra; Varenicline | 2018 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |